Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
View the Latest: Prescription Drugs
Filter
-
-
How Build Back Better Would Affect Drug Costs
FeatureProvisions in the bill that would lower prescription drug costs and reduce federal drug spending would take effect over the next several years, starting in 2023.
-
Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act
News ReleaseAs the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers.
-
Potential Costs and Impact of Health Provisions in the Build Back Better Act
Issue BriefA summary of 10 of the major health coverage and financing provisions of the current Build Back Better Act, with discussion of the potential implications for people and the federal budget.
-
Explaining the Prescription Drug Provisions in the Build Back Better Act
Issue BriefThe Build Back Better Act includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.
-
2021 Employer Health Benefits Survey
ReportThis annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers changed their mental health, telemedicine and other benefits in response to the COVID-19 pandemic.
-
A Record 3,834 Medicare Advantage Plans Will be Available in 2022, Up 8 Percent From 2021, While the Number of Medicare Part D Stand-Alone Plans is Decreasing Mainly Due to Firm Consolidations
News ReleaseA record 3,834 Medicare Advantage plans will be available across the country as alternatives to traditional Medicare for 2022, a new KFF analysis finds. That’s an increase of 8 percent from 2021, and the largest number of plans available in more than a decade.
-
Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2022
Issue BriefThis issue brief provides an overview of the Medicare Part D prescription drug benefit market for 2022, with a primary focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2022.
-
The Public Weighs In On Medicare Drug Negotiations
FeatureThis data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.
-
Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It
News ReleaseMost of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill –…